质子泵抑制剂的使用对帕博利珠单抗治疗晚期尿路上皮癌疗效的影响。
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
机构信息
Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
出版信息
Anticancer Res. 2022 Mar;42(3):1629-1634. doi: 10.21873/anticanres.15638.
BACKGROUND/AIM: This study aimed to clarify the impact of proton pump inhibitors (PPIs) on oncological outcomes in patients who received pembrolizumab for advanced urothelial carcinoma (UC).
PATIENTS AND METHODS
Forty advanced UC patients treated with pembrolizumab were retrospectively reviewed and divided into two groups (PPI: 15 patients; without PPI: 25 patients). Tumor response and survival were compared between these groups. The factors associated with survival were also investigated.
RESULTS
The objective response rate was significantly lower in the group with PPIs compared with the group without PPIs. Both progression-free survival (PFS) and overall survival (OS) were significantly shorter in the group with PPIs than in the group without PPIs. The use of PPIs was a significant predictor of poor PFS and OS in multivariate analysis.
CONCLUSION
The use of PPIs was negatively associated with tumor response and survival in patients with advanced UC treated with pembrolizumab.
背景/目的：本研究旨在阐明质子泵抑制剂 (PPI) 对接受派姆单抗治疗的晚期尿路上皮癌 (UC) 患者肿瘤学结局的影响。
患者与方法
回顾性分析了 40 例接受派姆单抗治疗的晚期 UC 患者，并将其分为两组（PPI：15 例；无 PPI：25 例）。比较两组之间的肿瘤反应和生存情况。还研究了与生存相关的因素。
结果
与无 PPI 组相比，PPI 组的客观缓解率显著降低。PPI 组的无进展生存期 (PFS) 和总生存期 (OS) 明显短于无 PPI 组。多因素分析显示，使用 PPI 是 PFS 和 OS 不良的显著预测因素。
结论
在接受派姆单抗治疗的晚期 UC 患者中，使用 PPI 与肿瘤反应和生存不良相关。
Zotero 插件